There are additional reports showing that: (A) tumorigenicity of fibrosarcoma cells was inhibited by EFEMP1 over-expression, (B) reduced EFEMP1 expression and/or EFEMP1 promoter methylation occurs in lung, liver, breast, prostate, and nasopharyngeal carcinomas [4-9], and (C) a decrease in EFEMP1 expression in hepatocellular and nasopharyngeal carcinoma is correlated with a worse prognosis [5,9]. This evidence concerns the gene EFEMP1 and nasopharyngeal carcinoma.